Aurobindo Pharma has informed that the board of Directors of the Company at its meeting held today, May 31, 2021, has based on the recommendation of the Nomination and Remuneration Committee and subject to the approval of the members in the forthcoming Annual General Meeting, has approved: the re-appointment of K. Nithyananda Reddy as Whole-time Director designated as Vice Chairman of the Company for a period of 3 years with effect from June 1,2021. He is related to P. Sarath Chandra Reddy, Whole-time Director of the Company, the re-appointment of N. Govindarajan as Managing Director of the Company for a period of 3 years with effect from June 1, 2021. He is not related to any other Directors of the Company, the re-appointment of M. Sivakumaran as Whole-time Director of the Company for a period of 3 years with effect from June 1, 2021. He is not related to any other Directors of the Company and the re-appointment of M. Madan Mohan Reddy as Whole-time Director of the Company for a period of 3 years with effect from June 1, 2021. He is not related to any other Directors of the Company. The company affirmed that K. Nithyananda Reddy, N. Govindarajan, M. Sivakumaran, and M. Madan Mohan Reddy are not debarred from holding the office of Director by virtue of any SEBI order or any such authority. A brief profile of K. Nithyananda Reddy, N. Govindarajan, M. Sivakumaran, and M. Madan Mohan are enclosed as Annexure. The Board meeting commenced at 9.00 am and concluded at 12:50 pm.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.95 |
| Dr. Reddys Lab | 1315.85 |
| Cipla | 1294.75 |
| Zydus Lifesciences | 927.15 |
| Lupin | 2296.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: